• Home Claus Vogelmeier.

Claus Vogelmeier.

Claus Vogelmeier, M.D., Bettina Hederer, M cialis online .D., Thomas Glaab, M.D., Hendrik Schmidt, Ph.D., Maureen P.M.H.D., Kai M. Beeh, M.D., Klaus F. Rabe, M.D., and Leonardo M. Fabbri, M.D. For the POET-COPD Investigators: Tiotropium versus Salmeterol for preventing Exacerbations of COPD Chronic obstructive pulmonary disease is a respected reason behind disability and death worldwide.1-3 Exacerbations of COPD indicate instability or worsening of the patient’s medical status and progression of the disease and have been associated with the advancement of complications, an increased threat of subsequent exacerbations, a worsening of coexisting conditions, reduced health status and exercise, deterioration of lung function, and an elevated risk of death.4-7 Preventing exacerbations therefore takes its major objective of treatment.1,2 Comparative studies have indicated that tiotropium is usually connected with a greater decrease in the risk of exacerbations and exacerbation-related hospitalizations than is usually salmeterol, even though differences were not significant.13,14 These were short-term studies and were not designed and powered to detect a notable difference in the chance of exacerbations.

Nussbaum, M.D., Robert Kleta, M.D., Ph.D., William A. Gahl, M.D., Ph.D., and Manfred Boehm, M.D.: NT5E Mutations and Arterial Calcifications.. Cynthia St. Hilaire, Ph.D., Shira G. Ziegler, B.A., Thomas C. Markello, M.D., Ph.D., Alfredo Brusco, Ph.D., Catherine Groden, M.S., Fred Gill, M.D., Hannah Carlson-Donohoe, B.A., Robert J. Lederman, M.D., Marcus Y. Chen, M.D., Dan Yang, M.D., Ph.D., Michael P. Siegenthaler, M.D., Carlo Arduino, M.D., Cecilia Mancini, M.Sc., Bernard Freudenthal, M.D., Horia C. Stanescu, M.D., Anselm A. Zdebik, M.D., Ph.D., R. Krishna Chaganti, M.D., Robert L.